相关实验视频

Updated: May 11, 2026

Tracking Hypoxic Signaling within Encapsulated Cell Aggregates
09:14

Tracking Hypoxic Signaling within Encapsulated Cell Aggregates

Published on: December 16, 2011

10.6K

一个长时间的腹膜住宿用icodextrin可以取代两个短暂的住宿用葡萄糖吗?

Joanna Stachowska-Pietka1,2, Jacek Waniewski1, Anna Olszowska3

  • 1Nalecz Institute of Biocybernetics and Biomedical Engineering, Polish Academy of Sciences, Warsaw, Poland.

Frontiers in physiology
|July 25, 2024
PubMed
概括

与葡萄糖相比,icodextrin溶液在腹腔透析中提供了更好的液体和溶液去除. 一个icodextrin交换可以有效地取代两个葡萄糖交换,提高超过效率和去除.

关键词:
慢性脏疾病 慢性脏疾病葡萄糖吸收 葡萄糖吸收在icodextrin中使用.腹膜透析是指腹膜透析.提取的提取方法超过是一种超过.超过的效率是超过的效率.

更多相关视频

Fat-Covered Islet Transplantation Using Epididymal White Adipose Tissue06:39

Fat-Covered Islet Transplantation Using Epididymal White Adipose Tissue

Published on: May 25, 2021

2.0K
Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

211

相关概念视频

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Peritoneal Dialysis I: Introduction and Procedure01:30

Peritoneal Dialysis I: Introduction and Procedure

Peritoneal dialysis (PD) is a procedure that facilitates the exchange of solutes, waste products, electrolytes, and excess fluid between the blood in the peritoneal capillaries and a dialysis solution introduced into the peritoneal cavity.Principles of Peritoneal Dialysis (PD)Diffusion: Waste products such as urea and electrolytes move from high concentrations in the blood to low concentrations in the dialysate across the peritoneal membrane. This mechanism is driven by the concentration...
Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications01:25

Peritoneal Dialysis II: Peritoneal Dialysis Systems and Complications

Peritoneal dialysis (PD) is a medical process that removes waste products and excess fluid from the body using the peritoneal membrane as a natural filter.Peritoneal Dialysis MethodsSeveral methods can be used for peritoneal dialysis, including Acute Intermittent Peritoneal Dialysis, Continuous Ambulatory Peritoneal Dialysis, and Automated Peritoneal Dialysis, also known as Continuous Cyclic Peritoneal Dialysis.Acute Intermittent Peritoneal Dialysis (AIPD) is used for patients with uremic...